Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306397 | 0.99 | PDPK1 (0.62) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL13306405 | 0.93 | PDPK1 (0.64) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL14309044 | 0.93 | PDPK1 (0.64) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL4989827 | 0.88 | MAPT (0.50) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL14090925 | 0.87 | MAPT (0.51) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL15871894 | 0.84 | PDPK1 (0.67) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL13306400 | 0.83 | PDPK1 (0.63) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL4430752 | 0.81 | C3AR1 (0.46) | PDPK1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL4989511 | 0.80 | BRD4 (0.53) | MAPTPOLBKMT2AMEN1RXFP1 | |
| SCHEMBL4989359 | 0.79 | BRD4 (0.54) | MAPTPOLBKMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PDPK1 5/4885MAPT 3341/4885POLB 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.